Morphosys AG: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Morphosys AG Increases FY 2013 Guidance
Morphosys AG announced that it has increased its financial guidance for full fiscal year 2013, and expects an EBIT of EUR 7 million to EUR 10 million (up from previously EUR 2 million to EUR 6 million) and revenues at the upper end of the previously communicated guidance range of EUR 74 million to EUR 78 million. According to I/B/E/S Estimates, analysts on average are expecting the Company to report fiscal year 2013 EBIT of EUR 7.12 million and revenue of EUR 72.87 million.
Latest Key Developments in Biotechnology
- MediBIC Group raises full-year consolidated revenue outlook for FY 2013
- Scancell Holdings PLC announces results from Part2 of trial in patients treated with SCIB1 ImmunoBody
- Karyopharm Therapeutics Inc presents promising data for Selinexor, an Oral, first-in-class selective inhibitors of Nuclear Export (SINE) Compound, in Hematologic Malignancies
- Alnylam Pharmaceuticals Inc announces pre-clinical results on ALN-CC5 demonstrate up to 98 pct Serum C5 Knockdown and up to 94 pct Inhibition of Hemol
- Share this
- Digg this